Your privacy is important to us at STAAR Surgical Company ("STAAR"). This privacy statement ("Statement") applies to STAAR Web sites, any mobile applications ("Apps") and digital platforms and services ("Services") (collectively, "Sites") and explains how we collect, use, disclose and otherwise process information that identifies you or from which you are identifiable (“Personal Information”). Please be sure to read this entire Statement before using or submitting information to our Sites.
Personal Information Collected We collect information from you in various ways when you use our Sites. We may collect Personal Information you directly provide on our Sites. In addition, we may collect Personal Information you generate as a user of our Sites or if you are a patient, which you provide to a healthcare professional or an institutional healthcare provider (collectively, "Providers"). Personal Information we may collect includes name, email address, phone number, gender, date of birth and zip code.
Where we collect and process Personal Information about your health or medical status (i.e., “Sensitive Personal Information”) this information may be subject to stricter requirements than other Personal Information. Before providing (or consenting to the disclosure of) Sensitive Personal Information to us, we urge you to carefully consider whether to disclose such information.
In addition, some information may be automatically collected when you visit our Sites – please see Section on Cookies below.
If you are a Provider, you are responsible for providing adequate notice to, and obtaining any legally required authorization, consent or other permission from, your patients prior to providing their Personal Information to STAAR through the Sites (though STAAR does not request patient Personal Information). By submitting any Personal Information about a patient to STAAR, you represent and warrant to STAAR that you have provided adequate notice to and obtained all required consents from patients to do so.
If you choose to participate in our questionnaires and surveys and other interactive Services, we will collect Personal Information that you disclose, to help us better understand how STAAR products are used in addressing visual conditions for which they are marketed.
The information you provide through interactive Services may be combined (subject to all applicable laws) with the Personal Information provided elsewhere in or through the Services. We may combine your and others' Personal Information to create summary data that we will use for our business purposes, such as research to improve our products and analyses that may help us better market our products.
If you submit Sensitive Personal Information (e.g., health-related information) through the Services to participate in a clinical trial, sweepstake or otherwise, we may use such Sensitive Personal Information to assess whether you qualify for enrollment or participation, to contact you about potential participation, and to provide you with additional information.
You may provide information to be published or displayed ("Posted") on public areas of the Services (collectively, "User Contribution"). If you post User Contributions then you do so at your own risk. STAAR does not control the actions of third parties with access to your User Contributions.
A "web beacon" is a piece of code that enables us to monitor user activity and website traffic. A "cookie" is a randomly-generated unique numeric code stored in the user's web browser settings or computer's hard drive. A cookie typically contains the name of the domain (internet location) from which the cookie originated, the "lifetime" of the cookie (i.e., when it expires), as well as the randomly generated unique numeric code.
We link the information we store in cookies to any personally identifiable information you submit while on our Sites. If you prefer not to receive cookies on this website, you can set your browser (such as internet explorer, Google Chrome, Mozilla Firefox, etc.) to warn you before accepting cookies and refuse the cookie when your browser alerts you to its presence. You can set your browser not to accept cookies, but if you do so or if you reject a cookie, you may not be able to access some of the features or services of our Sites. We may track your activities over time and across third-party websites, apps or other online services to display advertisements on third-party websites. If you do not want us to use your information in this way, please see "Your Privacy Choices" below. For more information about our digital advertising practices, please see "Digital Advertising" below.
Facebook Pixel. We use Facebook Pixel on our Discover ICL site to track visits to the site and to analyze the content a Facebook user has viewed when visiting the Discover ICL site (e.g., EVO Visian ICL videos) in order to measure, optimize and improve the content of the site. This Pixel records information about a Facebook user's session on the Discover ICL website, which it sends to Facebook, along with an anonymised version of the user’s Facebook ID. We collect and store information gathered from the session Facebook Pixel cookie for 180 days. You can delete the Facebook Pixel cookie and other cookies at any time by clearing your browser cache. For further information about the Facebook Pixel please see: https://en-gb.facebook.com/business/help/651294705016616.
Facebook Lead Ad: We use the Facebook Lead Ad to collect users’ full name, email address, city, and postal zip code. STAAR uses this data to contact the user via e-mail to send contact information about EVO Visian ICL certified clinic(s). The user’s data will not be transmitted to the clinics in this process.
Connecting with Social Media through the Services
Certain Services may link with social media platforms and social media plug-ins (e.g., the Facebook "Like" button, "Share to Twitter" button) (collectively, "Social Media"). When accessing the Services through a Facebook or other Social Media account, STAAR may (depending on the applicable user privacy settings) automatically have access to information provided to or through the Social Media platform. STAAR may collect and use this information for the purposes described in this Privacy Statement or at the time the information was collected.
Connecting with Social Media through Service Providers
Third parties that assist us with our business operations also collect and use information (including Personal Information and "Usage Data" (i.e., information about an individual's activity on or through the Services that, by itself, does not identify the individual, such as browser type, operating system and webpages visited)) through the Services and also may share the collected information with us. For example, our vendors collect and share information with us to analyze use of the Services, to help us detect and prevent fraud and to improve user experience.
Ready to Discover Visual Freedom With EVO? Find a Doctor Today
Important Safety Information
It is important to consider that EVO Visian® Implantable Collamer Lenses (ICL) are approved by the local health authority, which means they have been determined to be safe and effective. As with any procedure, there are risks to consider. If you have any questions or concerns it is always best to speak with a certified EVO Visian® Implantable Collamer Lens (ICL) doctor. The EVO Visian ICL family of lenses include EVO Visian ICL, EVO Visian Toric ICL, EVO+ Visian ICL, and EVO+ Visian Toric ICL and are designed for the correction/reduction of low to high myopia (-0.5 to -20.0 diopters (D)) and the correction/reduction of myopia in patients with up to -20 D of myopia with less than or equal to 6.0 D of astigmatism. The EVO Visian ICL family is indicated for use in phakic eye treatment and for: The correction/reduction of myopia in adults 21 – 60 years of age with power ranging from -0.5 D to -20.0 D at the spectacle plane. With an anterior chamber depth (ACD) equal to or greater than 3.0 mm, as measured from the corneal endothelium to the anterior lens capsule. This extended age range covering over 45 to 60 years of age only applies to the myopic EVO Visian ICL family, and only in countries covered by the jurisdiction of the EU Notified Bodies where the CE Mark is recognised (i.e., the EU, EEA, and EFTA). The EVO Visian ICL family of products currently in inventory do not have the updated Directions For Use (DFU) with this new wording yet, but it will be incorporated over time. EVO Visian ICL surgery does not eliminate the need for reading glasses, even if you have never worn them before. The EVO Visian ICL represents an alternative to other refractive surgeries including, laser assisted in situ keratomileusis (LASIK), photorefractive keratectomy (PRK), incisional surgeries, or other means to correct myopia such as contact lenses and eye glasses. The EVO Visian Toric ICL is intended to correct or reduce astigmatism (up to 6.0 D) you may have (the EVO Visian ICL is not intended to treat your astigmatism). Implantation of an EVO Visian ICL is a surgical procedure, and as such, carries potentially serious risks. The following represent potential complications/adverse reactions reported in conjunction with refractive surgery in general: additional surgeries, cataract formation, loss of best corrected vision, raised pressure inside the eye, loss of cells on the innermost surface of the cornea, conjunctival irritation, acute corneal swelling, persistent corneal swelling, endophthalmitis (total eye infection), significant glare and/or halos around lights, hyphaema (blood in the eye), hypopyon (pus in the eye), eye infection, Visian ICL dislocation, macular oedema, non-reactive pupil, pupillary block glaucoma, severe inflammation of the eye, iritis, uveitis, vitreous loss and corneal transplant. Before considering EVO Visian ICL surgery you should have a complete eye examination and talk with your eye care professional about EVO Visian ICL surgery, especially the potential benefits, risks and complications. You should discuss the time needed for healing after surgery.
1. Patient Survey, STAAR Surgical ICL Data Registry, 2018
2. Sanders D. Vukich JA. Comparison of implantable collamer lens (ICL) and laser-assisted in situ keratomileusis (LASIK) for Low Myopia. Cornea. 2006 Dec; 25(10):1139-46. Patient Survey, STAAR Surgical ICL Data Registry, 2018
3. Naves, J.S. Carracedo, G. Cacho-Babillo, I. Diadenosine Nucleotid Measurements as Dry-Eye Score in Patients After LASIK and ICL Surgery. Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2012.
4. Shoja, MR. Besharati, MR. Dry eye after LASIK for myopia: Incidence and risk factors. European Journal of Ophthalmology. 2007; 17(1): pp. 1-6.
5a. Lee, Jae Bum et al. Comparison of tear secretion and tear film instability after photorefractive keratectomy and laser in situ keratomileusis. Journal of Cataract & Refractive Surgery , Volume 26 , Issue 9 , 1326 - 1331.
5b. Parkhurst, G. Psolka, M. Kezirian, G. Phakic intraocular lens implantantion in United States military warfighters: A retrospective analysis of early clinical outcomes of the Visian ICL. J Refract Surg. 2011;27(7):473-481.